Cryo-EM structure of the human somatostatin receptor 2 complex with its agonist somatostatin delineates the ligand binding specificity

  1. Yunseok Heo
  2. Eojin Yoon
  3. Ye-Eun Jeon
  4. Ji-Hye Yun
  5. Naito Ishimoto
  6. Hyeonuk Woo
  7. Sam-Yong Park
  8. Ji-Joon Song  Is a corresponding author
  9. Weontae Lee  Is a corresponding author
  1. Yonsei University, Republic of Korea
  2. Korea Advanced Institute of Science and Technology, Republic of Korea
  3. Yokohama City University, Japan
  4. Seoul National University, Republic of Korea

Abstract

Somatostatin is a peptide hormone that regulates endocrine systems by binding to G-protein-coupled somatostatin receptors. Somatostatin receptor 2 (SSTR2) is a human somatostatin receptor and is highly implicated in hormone disorders, cancers and neurological diseases. Here, we report the high resolution cryo-EM structure of full-length human SSTR2 bound to the agonist somatostatin (SST-14) in complex with inhibitory G (Gi) proteins. Our structural and mutagenesis analyses show that seven transmembrane helices form a deep pocket for ligand binding and that SSTR2 recognizes the highly conserved Trp-Lys motif of SST-14 at the bottom of the pocket. Furthermore, our sequence analysis combined with AlphaFold modeled structures of other SSTR isoforms provide a structural basis for the mechanism by which SSTR family proteins specifically interact with their cognate ligands. This work provides the first glimpse into the molecular recognition mechanism of somatostatin receptors and a crucial resource to develop therapeutics targeting somatostatin receptors.

Data availability

The cryo-EM map and the model are to be deposited at EMDB (www.ebi.ac.uk) and RCSB (www.rcsb.org) data base with the accession codes of EMD-32543 and 7WJ5, respectively.

The following data sets were generated

Article and author information

Author details

  1. Yunseok Heo

    Department of Biochemistry, Yonsei University, Seoul, Republic of Korea
    Competing interests
    No competing interests declared.
  2. Eojin Yoon

    Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea
    Competing interests
    No competing interests declared.
  3. Ye-Eun Jeon

    Department of Biochemistry, Yonsei University, Seoul, Republic of Korea
    Competing interests
    No competing interests declared.
  4. Ji-Hye Yun

    Department of Biochemistry, Yonsei University, Seoul, Republic of Korea
    Competing interests
    Ji-Hye Yun, is an employee at PCG-Biotech and holds a research director position..
  5. Naito Ishimoto

    Drug Design Laboratory, Yokohama City University, Yokohama, Japan
    Competing interests
    No competing interests declared.
  6. Hyeonuk Woo

    Department of Chemistry, Seoul National University, Seoul, Republic of Korea
    Competing interests
    No competing interests declared.
  7. Sam-Yong Park

    Drug Design Laboratory, Yokohama City University, Yokohama, Japan
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6164-8896
  8. Ji-Joon Song

    Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea
    For correspondence
    songj@kaist.ac.kr
    Competing interests
    Ji-Joon Song, is a co-founder of PCG-Biotech.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7120-6311
  9. Weontae Lee

    Department of Biochemistry, Yonsei University, Seoul, Republic of Korea
    For correspondence
    wlee@spin.yonsei.ac.kr
    Competing interests
    Weontae Lee, is a co-founder of PCG-Biotech.

Funding

National Research Foundation of Korea (NRF-2020M3A9G7103934)

  • Ji-Joon Song

National Research Foundation of Korea (NRF-2020M3A9G7103934)

  • Weontae Lee

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2022, Heo et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,259
    views
  • 531
    downloads
  • 14
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yunseok Heo
  2. Eojin Yoon
  3. Ye-Eun Jeon
  4. Ji-Hye Yun
  5. Naito Ishimoto
  6. Hyeonuk Woo
  7. Sam-Yong Park
  8. Ji-Joon Song
  9. Weontae Lee
(2022)
Cryo-EM structure of the human somatostatin receptor 2 complex with its agonist somatostatin delineates the ligand binding specificity
eLife 11:e76823.
https://doi.org/10.7554/eLife.76823

Share this article

https://doi.org/10.7554/eLife.76823

Further reading

    1. Structural Biology and Molecular Biophysics
    Manming Xu, Sarath Chandra Dantu ... Shozeb Haider
    Research Article

    The relationship between protein dynamics and function is essential for understanding biological processes and developing effective therapeutics. Functional sites within proteins are critical for activities such as substrate binding, catalysis, and structural changes. Existing computational methods for the predictions of functional residues are trained on sequence, structural, and experimental data, but they do not explicitly model the influence of evolution on protein dynamics. This overlooked contribution is essential as it is known that evolution can fine-tune protein dynamics through compensatory mutations either to improve the proteins’ performance or diversify its function while maintaining the same structural scaffold. To model this critical contribution, we introduce DyNoPy, a computational method that combines residue coevolution analysis with molecular dynamics simulations, revealing hidden correlations between functional sites. DyNoPy constructs a graph model of residue–residue interactions, identifies communities of key residue groups, and annotates critical sites based on their roles. By leveraging the concept of coevolved dynamical couplings—residue pairs with critical dynamical interactions that have been preserved during evolution—DyNoPy offers a powerful method for predicting and analysing protein evolution and dynamics. We demonstrate the effectiveness of DyNoPy on SHV-1 and PDC-3, chromosomally encoded β-lactamases linked to antibiotic resistance, highlighting its potential to inform drug design and address pressing healthcare challenges.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Assmaa Elsheikh, Camden M Driggers ... Show-Ling Shyng
    Research Article

    Pancreatic KATP channel trafficking defects underlie congenital hyperinsulinism (CHI) cases unresponsive to the KATP channel opener diazoxide, the mainstay medical therapy for CHI. Current clinically used KATP channel inhibitors have been shown to act as pharmacochaperones and restore surface expression of trafficking mutants; however, their therapeutic utility for KATP trafficking-impaired CHI is hindered by high affinity binding, which limits functional recovery of rescued channels. Recent structural studies of KATP channels employing cryo-electron microscopy (cryoEM) have revealed a promiscuous pocket where several known KATP pharmacochaperones bind. The structural knowledge provides a framework for discovering KATP channel pharmacochaperones with desired reversible inhibitory effects to permit functional recovery of rescued channels. Using an AI-based virtual screening technology AtomNet followed by functional validation, we identified a novel compound, termed Aekatperone, which exhibits chaperoning effects on KATP channel trafficking mutations. Aekatperone reversibly inhibits KATP channel activity with a half-maximal inhibitory concentration (IC50) ~9 μM. Mutant channels rescued to the cell surface by Aekatperone showed functional recovery upon washout of the compound. CryoEM structure of KATP bound to Aekatperone revealed distinct binding features compared to known high affinity inhibitor pharmacochaperones. Our findings unveil a KATP pharmacochaperone enabling functional recovery of rescued channels as a promising therapeutic for CHI caused by KATP trafficking defects.